Invasive Aspergillosis in Patients with Hematologic Malignancies

Pharmacotherapy

Volumn 23, Issue 12 I, 2003, Pages 1592-1610

  Wiederhold, Nathan P ^a,b   Lewis, Russell E ^a,b   Kontoyiannis, Dimitrios P ^b  

^a UNIVERSITY OF HOUSTON   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Antifungal therapy; Aspergillosis; Hematologic malignancies

Indexed keywords

AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; ANTIHISTAMINIC AGENT; ANTIPYRETIC AGENT; BENZODIAZEPINE; CASPOFUNGIN; CORTICOSTEROID; FLUCONAZOLE; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; ITRACONAZOLE; MICAFUNGIN; OPIATE; POSACONAZOLE; RAVUCONAZOLE; VORICONAZOLE;

ASPERGILLOSIS; ASPERGILLUS; BONE MARROW; CHEMOPROPHYLAXIS; CHILL; CLINICAL TRIAL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DIAGNOSTIC APPROACH ROUTE; DIARRHEA; DISEASE COURSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG MEGADOSE; DRUG SCREENING; EPIDEMIOLOGICAL DATA; EYE PAIN; FEVER; GASTROINTESTINAL SYMPTOM; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; LIVER TOXICITY; LONG TERM CARE; MORTALITY; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; PATHOGENESIS; RASH; RECURRENT DISEASE; REVIEW; RISK FACTOR; TASTE DISORDER; URTICARIA; VISUAL DISORDER; VISUAL HALLUCINATION;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; CLINICAL TRIALS; CROSS INFECTION; DIAGNOSIS, DIFFERENTIAL; DRUG THERAPY, COMBINATION; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOTHERAPY; INFECTION CONTROL; OPPORTUNISTIC INFECTIONS;

EID: 0344874251     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.23.15.1592.31965     Document Type: Review

References (155)

1. Denning DW. Therapeutic outcome in invasive aspergillosis. Clin Infect Dis 1996;23:608-15.
2. Latge JP. Aspergillus fumigatus and aspergillosis. Clin Microbiol Rev 1999;12:310-50.
3. De La Rosa GR, Champlin RE, Kontoyiannis DP. Risk factors for the development of invasive fungal infections in allogeneic blood and marrow transplant recipients. Transpl Infect Dis 2002;4:3-9.
4. Baddley JW, Stroud TP, Salzman D, Pappas PG. Invasive mold infections in allogeneic bone marrow transplant recipients. Clin Infect Dis 2001;32:1319-24.
5. Boutboul F, Alberti C, Leblanc T, et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: increasing antigenemia is associated with progressive disease. Clin Infect Dis 2002;34:939-43.
6. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002;34:909-17.
7. Ribaud P, Chastang C, Latge JP, et al. Survival and prognostic factors of invasive aspergillosis after allogeneic bone marrow transplantation. Clin Infect Dis 1999;28:322-30.
8. Wald A, Leisenring W, van Burik JA, Bowden RA. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 1997;175:1459-66.
9. Rodriguez-Adrian LJ, Grazziutti ML, Rex JH, Anaissie EJ. The potential role of cytokine therapy for fungal infections in patients with cancer: is recovery from neutropenia all that is needed? Clin Infect Dis 1998;26:1270-8.
10. Kontoyiannis DP, Bodey GP. Invasive aspergillosis in 2002: an update. Eur J Clin Microbiol Infect Dis 2002;21:161-72.
11. Stone RM. Treatment of acute myeloid leukemia: state-of-the-art and future directions. Semin Hematol 2002;39:4-10.
12. Tallman MS, Hakimian D. Purine nucleoside analogs: emerging roles in indolent lymphoproliferative disorders. Blood 1995;86:2463-74.
13. Storek J, Dawson MA, Storer B, et al. Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. Blood 2001;97:3380-9.
14. Dasbach EJ, Davies GM, Teutsch SM. Burden of aspergillosis-related hospitalizations in the United States. Clin Infect Dis 2000;31:1524-8.
15. Marr KA, Patterson T, Denning D. Aspergillosis: pathogenesis, clinical manifestations, and therapy. Infect Dis Clin North Am 2002;16(4):875-94.
16. McNeil MM, Nash SL, Hajjeh RA, et al. Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin Infect Dis 2001;33:641-7.
17. Winston DJ, Chandrasekar PH, Lazarus HM, et al. Fluconazole prophylaxis of fungal infections in patients with acute leukemia: results of a randomized placebo-controlled, double-blind, multicenter trial. Ann Intern Med 1993;118:495-503.
18. Slavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation: a prospective, randomized, double-blind study. J Infect Dis 1995;171:1545-52.
19. Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992;326:845-51.
20. Marr KA, Seidel K, Slavin MA, et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood 2000;96:2055-61.
21. Kontoyiannis DP, Reddy BT, Hanna H, Bodey GP, Tarrand J, Raad II. Breakthrough candidemia in patients with cancer differs from de novo candidemia in host factors and Candida species but not intensity. Infect Control Hosp Epidemiol 2002;23:542-5.
22. Edmond MB, Wallace SE, McClish DK, Pfaller MA, Jones RN, Wenzel RP. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis 1999;29:239-44.
23. Abbas J, Bodey GP, Hanna HA, et al. Candida krusei fungemia: an escalating serious infection in immunocompromised patients. Arch Intern Med 2000;160:2659-64.
24. Bodey GP, Mardani M, Hanna HA, et al. The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer. Am J Med 2002;112:380-5.
25. van Burik JH, Leisenring W, Myerson D, et al. The effect of prophylactic fluconazole on the clinical spectrum of fungal diseases in bone marrow transplant recipients with special attention to hepatic candidiasis: an autopsy study of 355 patients. Medicine (Baltimore) 1998;77:246-54.
26. Alangaden GJ, Wahiduzzaman M, Chandrasekar PH. Aspergillosis: the most common community-acquired pneumonia with gram-negative bacilli as copathogens in stem cell transplant recipients with graft-versus-host disease. Clin Infect Dis 2002;35:659-64.
27. Nosari A, Oreste P, Cairoli R, et al. Invasive aspergillosis in haematological malignancies: clinical findings and management for intensive chemotherapy completion. Am J Hematol 2001;68:231-6.
28. Cheson BD. Infectious and immunosuppressive complications of purine analog therapy. J Clin Oncol 1995;13:2431-48.
29. Anaissie EJ, Kontoyiannis DP, O'Brien S, et al. Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Ann Intern Med 1998;129:559-66.
30. Tallman MS. Monoclonal antibody therapies in leukemias. Semin Hematol 2002;39:12-19.
31. Gokbuget N, Hoelzer D. The role of high-dose cytarabine in induction therapy for adult ALL. Leuk Res 2002;26:473-6.
32. Kern W, Schleyer E, Braess J, et al. Efficacy of fludarabine, intermittent sequential high-dose cytosine arabinoside, and mitoxantrone (FIS-HAM) salvage therapy in highly resistant acute leukemias. Ann Hematol 2001;80:334-9.
33. Kimby E, Nygren P, Glimelius B. A systematic overview of chemotherapy effects in acute myeloid leukaemia. Acta Oncol 2001;40:231-52.
34. Nguyen Q, Estey E, Raad I, et al. Cytomegalovirus pneumonia in adults with leukemia: an emerging problem. Clin Infect Dis 2001;32:539-45.
35. Denning DW. Invasive aspergillosis. Clin Infect Dis 1998;26:781-805.
36. Schmitt HJ, Blevins A, Sobeck K, Armstrong D. Aspergillus species from hospital air and from patients. Mycoses 1990;33:539-41.
37. Tomee JF, Kauffman HF. Putative virulence factors of Aspergillus fumigatus. Clin Exp Allergy 2000;30:476-84.
38. Latge JP. The pathobiology of Aspergillus fumigatus. Trends Microbiol 2001;9:382-9.
39. Chandler F, Kaplan W, Ajelloa L. Color atlas and text of the histopathology of mycotic diseases. Chicago: Year Book Medical Publishers, 1980.
40. Chang HY, Rodriguez V, Narboni G, Bodey GP, Luna MA, Freireich EJ. Causes of death in adults with acute leukemia. Medicine (Baltimore) 1976;55:259-68.
41. Estey EH, Keating MJ, McCredie KB, Bodey GP, Freireich EJ. Causes of initial remission induction failure in acute myelogenous leukemia. Blood 1982;60:309-15.
42. Schaffner A. Macrophage-Aspergillus interactions. Immunol Ser 1994;60:545-52.
43. Schaffner A, Douglas H, Braude A. Selective protection against conidia by mononuclear and against mycelia by polymorphonuclear phagocytes in resistance to Aspergillus: observations on these two lines of defense in vivo and in vitro with human and mouse phagocytes. J Clin Invest 1982;69:617-31.
44. Clemons KV, Calich VL, Burger E, et al. Pathogenesis I: interactions of host cells and fungi. Med Mycol 2000;38(suppl 1):99-111.
45. Garlanda C, Hirsch E, Bozza S, et al. Non-redundant role of the long pentraxin PTX3 in anti-fungal innate immune response. Nature 2002;420:182-6.
46. Schaffner A, Schaffner T. Glucocorticoid-induced impairment of macrophage antimicrobial activity: mechanisms and dependence on the state of activation. Rev Infect Dis 1987;9(suppl 5):S620-9.
47. Cenci E, Perito S, Enssle KH, et al. Th1 and Th2 cytokines in mice with invasive aspergillosis. Infect Immun 1997;65:564-70.
48. Cenci E, Mencacci A, Fe d'Ostiani C, et al. Cytokine- and T helper-dependent lung mucosal immunity in mice with invasive pulmonary aspergillosis. J Infect Dis 1998;178:1750-60.
49. Roilides E, Sein T, Roden M, Schaufele RL, Walsh TJ. Elevated serum concentrations of interleukin-10 in nonneutropenic patients with invasive aspergillosis. J Infect Dis 2001;183:518-20.
50. Hebart H, Bollinger C, Fisch P, et al. Analysis of T-cell responses to Aspergillus fumigatus antigens in healthy individuals and patients with hematologic malignancies. Blood 2002;100:4521-8.
51. Casadevall A. Acquired immunity against fungi. In: Ahmed R, ed. Immunology of infectious diseases. Washington, DC: American Society for Microbiology Press, 2002.
52. Cenci E, Mencacci A, Del Sero G, et al. Interleukin-4 causes susceptibility to invasive pulmonary aspergillosis through suppression of protective type I responses. J Infect Dis 1999;180:1957-68.
53. Del Sero G, Mencacci A, Cenci E, et al. Antifungal type 1 responses are upregulated in IL-10-deficient mice. Microbes Infect 1999;1:1169-80.
54. Nagai H, Guo J, Choi H, Kurup V. Interferon-gamma and tumor necrosis factor-alpha protect mice from invasive aspergillosis. J Infect Dis 1995;172:1554-60.
55. Kataoka Y, Iwasaki T, Kuroiwa T, et al. The role of donor T cells for target organ injuries in acute and chronic graft-versus-host disease. Immunology 2001;103:310-18.
56. Imamura M, Tsutsumi Y, Miura Y, Toubai T, Tanaka J. Immune reconstitution and tolerance after allogeneic hematopoietic stem cell transplantation. Hematology 2003;8:19-26.
57. Mullbacher A, Eichner RD. Immunosuppression in vitro by a metabolite of a human pathogenic fungus. Proc Natl Acad Sci U S A 1984;81:3835-7.
58. Mullbacher A, Waring P, Eichner RD. Identification of an agent in cultures of Aspergillus fumigatus displaying antiphagocytic and immunomodulating activity in vitro. J Gen Microbiol 1985;131(pt 5):1251-8.
59. Mullbacher A, Moreland AF, Waring P, Sjaarda A, Eichner RD. Prevention of graft-versus-host disease by treatment of bone marrow with gliotoxin in fully allogeneic chimeras and their cytotoxic T cell repertoire. Transplantation 1988;46:120-5.
60. Brakhage AA, Langfelder K. Menacing mold: the molecular biology of Aspergillus fumigatus. Annu Rev Microbiol 2002;56:433-55.
61. Jantunen E, Volin L, Salonen O, et al. Central nervous system aspergillosis in allogeneic stem cell transplant recipients. Bone Marrow Transplant 2003;31:191-6.
62. Richardson MD. Aspergillus. In: Pfaller MA, ed. Clinical mycology. New York: Churchill Livingstone, 2003.
63. Caillot D, Couaillier JF, Bernard A, et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol 2001;19:253-9.
64. Stevens DA, Kan VL, Judson MA, et al. Practice guidelines for diseases caused by Aspergillus: Infectious Diseases Society of America. Clin Infect Dis 2000;30:696-709.
65. Heussel CP, Kauczor HU, Heussel GE, et al. Pneumonia in febrile neutropenic patients and in bone marrow and blood stem-cell transplant recipients: use of high-resolution computed tomography. J Clin Oncol 1999;17:796-805.
66. Caillot D, Casasnovas O, Bernard A, et al. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol 1997;15:139-47.
67. Horvath JA, Dummer S. The use of respiratory-tract cultures in the diagnosis of invasive pulmonary aspergillosis. Am J Med 1996;100:171-8.
68. Perfect JR, Cox GM, Lee JY, et al. The impact of culture isolation of Aspergillus species: a hospital-based survey of aspergillosis. Clin Infect Dis 2001;33:1824-33.
69. Kontoyiannis DP, Sumoza D, Tarrand J, Bodey GP, Storey R, Raad II. Significance of aspergillemia in patients with cancer: a 10-year study. Clin Infect Dis 2000;31:188-9.
70. Alexander BD. Diagnosis of fungal infection: new technologies for the mycology laboratory. Transpl Infect Dis 2002;4(suppl 3):32-7.
71. Denning DW. Early diagnosis of invasive aspergillosis. Lancet 2000;355:423-4.
72. Maertens J, Verhaegen J, Demuynck H, et al. Autopsy-controlled prospective evaluation of serial screening for circulating galactomannan by a sandwich enzyme-linked immunosorbent assay for hematological patients at risk for invasive aspergillosis. J Clin Microbiol 1999;37:3223-8.
73. Maertens J, Verhaegen J, Lagrou K, Van Eldere J, Boogaerts M. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood 2001;97:1604-10.
74. Pinel C, Fricker-Hidalgo H, Lebeau B, et al. Detection of circulating Aspergillus fumigatus galactomannan: value and limits of the platelia test for diagnosing invasive aspergillosis. J Clin Microbiol 2003;41:2184-6.
75. Kawamura S, Maesaki S, Noda T, et al. Comparison between PCR and detection of antigen in sera for diagnosis of pulmonary aspergillosis. J Clin Microbiol 1999;37:218-20.
76. Einsele H, Hebart H, Roller G, et al. Detection and identification of fungal pathogens in blood by using molecular probes. J Clin Microbiol 1997;35:1353-60.
77. Ascioglu S, de Pauw BE, Donnelly JP, Collette L. Reliability of clinical research on invasive fungal infections: a systematic review of the literature. Med Mycol 2001;39:35-40.
78. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002;34:7-14.
79. Subira M, Martino R, Rovira M, Vazquez L, Serrano D, De La Camara R. Clinical applicability of the new EORTC/MSG classification for invasive pulmonary aspergillosis in patients with hematological malignancies and autopsy-confirmed invasive aspergillosis. Ann Hematol 2003;82:80-2.
80. Patterson TF, Kirkpatrick WR, White M, et al. Invasive aspergillosis: disease spectrum, treatment practices, and outcomes: 13 Aspergillus study group. Medicine (Baltimore) 2000;79:250-60.
81. Denning DW. Aspergillus species. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and practices of infectious diseases 5th ed, vol 2. Philadelphia: Churchill Livingston, 2000.
82. Denning DW, Stevens DA. Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases. Rev Infect Dis 1990;12:1147-201.
83. Ringden O, Meunier F, Tollemar J, et al. Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients. J Antimicrob Chemother 1991;28(suppl B):73-82.
84. Denning DW, Lee JY, Hostetler JS, et al. NIAID mycoses study group multicenter trial of oral itraconazole therapy for invasive aspergillosis. Am J Med 1994;97:135-44.
85. Hiemenz JW, Lister J, Anaissie EJ, et al. Emergency-use amphotericin B lipid complex in the treatment of patients with aspergillosis: historical control comparison with amphotericin B. Presented at the 37th annual meeting of the American Society of Hematology, Seattle, WA, December 1-5, 1995.
86. Oppenheim BA, Herbrecht R, Kusne S. The safety and efficacy of amphotericin B colloidal dispersion in the treatment of invasive mycoses. Clin Infect Dis 1995;21:1145-53.
87. Wingard JR. Efficacy of amphotericin B lipid complex injection (ABLC) in bone marrow transplant recipients with life-threatening systemic mycoses. Bone Marrow Transplant 1997;19:343-7.
88. Walsh TJ, Hiemenz JW, Seibel NL, et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998;26:1383-96.
89. Maertens J, Raad I, Petrikkos G, et al. Update of the multicenter noncomparative study of caspofungin (cas) in adults with invasive aspergillosis (ia) refractory or intolerant to other antifungal agents: analysis of 90 patients. Presented at the 42nd interscience conference on antimicrobial agents and chemotherapy, San Diego, CA, September 27-30, 2002.
90. Denning DW, Ribaud P, Milpied N, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002;34:563-71.
91. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347:408-15.
92. Bowden R, Chandrasekar P, White MH, et al. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 2002;35:359-66.
93. Ellis M, Spence D, de Pauw B, et al. An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis. Clin Infect Dis 1998;27:1406-12.
94. Leenders AC, Daenen S, Jansen RL, et al. Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. Br J Haematol 1998;103:205-12.
95. Wingard JR, Kubilis P, Lee L, et al. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis 1999;29:1402-7.
96. Wingard JR. Lipid formulations of amphotericins: are you a lumper or a splitter? Clin Infect Dis 2002;35:891-5.
97. Anaissie EJ, Mattiuzzi GN, Miller CB, et al. Treatment of invasive fungal infections in renally impaired patients with amphotericin B colloidal dispersion. Antimicrob Agents Chemother 1998;42:606-11.
98. Kontoyiannis DP, Andersson BS, Lewis RE, Raad II. Progressive disseminated aspergillosis in a bone marrow transplant recipient: response with a high-dose lipid formulation of amphotericin B. Clin Infect Dis 2001;32:E94-6.
99. Kline S, Larsen TA, Fieber L, et al. Limited toxicity of prolonged therapy with high doses of amphotericin B lipid complex. Clin Infect Dis 1995;21:1154-8.
100. Walsh TJ, Goodman JL, Pappas P, et al. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob Agents Chemother 2001;45:3487-96.
101. Boogaerts M, Maertens J. Clinical experience with itraconazole in systemic fungal infections. Drugs 2001;61(suppl 1):39-47.
102. Boogaerts MA, Verhoef GE, Zachee P, Demuynck H, Verbist L, De Beule K. Antifungal prophylaxis with itraconazole in prolonged neutropenia: correlation with plasma levels. Mycoses 1989;32(suppl 1):103-8.
103. Stevens DA, Lee JY. Analysis of compassionate use itraconazole therapy for invasive aspergillosis by the NIAID mycoses study group criteria. Arch Intern Med 1997;157:1857-62.
104. De Beule K, De Doncker P, Cauwenbergh G, et al. The treatment of aspergillosis and aspergilloma with itraconazole: clinical results of an open international study (1982-1987). Mycoses 1988;31:476-85.
105. Heykants J, Van Peer A, Van de Velde V, et al. The clinical pharmacokinetics of itraconazole: an overview. Mycoses 1989;32(suppl 1):67-87.
106. Groll AH, Piscitelli SC, Walsh TJ. Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. Adv Pharmacol 1998;44:343-500.
107. Caillot D, Bassaris H, McGeer A, et al. Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS [online exclusive article]. Clin Infect Dis 2001;33:e83-90. Available from http://www.journals.uchicago.edu/CID/journal/contents/v33n8.html.
108. Prentice HG, Caillot D, Dupont B, Menichetti F, Schuler U. Oral and intravenous itraconazole for systemic fungal infections in neutropenic haematological patients: meeting report: London, United Kingdom, 20 June 1998. Acta Haematol 1999;101:56-62.
109. Stevens DA. Itraconazole in cyclodextrin solution. Pharmacotherapy 1999;19:603-11.
110. Marr KA, Crippa F, Leisenring W, et al. Itraconazole vs. fluconazole for antifungal prophylaxis in allogeneic HSCT recipients: results of a randomized trial. Presented at the 44th annual meeting of the American Society of Hematology, Philadelphia, PA, December 6-10, 2002.
111. Schwartz S, Milatovic D, Thiel E. Successful treatment of cerebral aspergillosis with a novel triazole (voriconazole) in a patient with acute leukaemia. Br J Haematol 1997;97:663-5.
112. Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis 2003;36:630-7.
113. Ernst EJ. Investigational antifungal agents. Pharmacotherapy 2001;21:165S-74.
114. Pfaller MA, Messer SA, Hollis RJ, Jones RN. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY antimicrobial surveillance program, 2000. Antimicrob Agents Chemother 2002;46:1032-7.
115. Petraitiene R, Petraitis V, Groll AH, et al. Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia. Antimicrob Agents Chemother 2001;45:857-69.
116. Roberts J, Schock K, Marino S, Andriole VT. Efficacies of two new antifungal agents, the triazole ravuconazole and the echinocandin LY-303366, in an experimental model of invasive aspergillosis. Antimicrob Agents Chemother 2000;44:3381-8.
117. Hachem R, Raad I, Afif C, et al. An open-label, noncomparative multicenter study to evaluate the efficacy and safety of posaconazole (SCH56592) in the treatment of invasive fungal infections refractory or intolerant to standard therapy. Presented at the 40th interscience conference on antimicrobial agents and chemotherapy, Toronto, Ontario, September 17-20, 2000.
118. Kurtz MB, Heath IB, Marrinan J, Dreikorn S, Onishi J, Douglas C. Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-beta-D-glucan synthase. Antimicrob Agents Chemother 1994;38:1480-9.
119. Merck & Co., Inc. Cancidas (caspofungin) package insert. Whitehouse Station, NJ; 2001.
120. Bowman JC, Hicks PS, Kurtz MB, et al. The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro. Antimicrob Agents Chemother 2002;46:3001-12.
121. Beauvais A, Bruneau JM, Mol PC, Buitrago MJ, Legrand R, Latge JP. Glucan synthase complex of Aspergillus fumigatus. J Bacteriol 2001;183:2273-9.
122. van Burik J, Ratanatharathorn V, Lipton J, Miller C, Bunin N, Walsh TJ. Randomized, double-blind trial of micafungin versus fluconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplant, NIAID/BAMSG protocol 46. Presented at the 42nd interscience conference on antimicrobial agents and chemotherapy, San Diego, CA, September 27-30, 2002.
123. Ratanatharathorn V, Flynn P, van Burik J, McSweeney P, Niederwieser D, Kontoyiannis DP. Micafungin in combination with systemic antifungal agents in the treatment of refractory aspergillosis in bone marrow transplant patients. Presented at the 44th annual meeting of the American Society of Hematology, Philadelphia, PA, December 6-10, 2002.
124. Iwen PC, Davis JC, Reed EC, Winfield BA, Hinrichs SH. Airborne fungal spore monitoring in a protective environment during hospital construction, and correlation with an outbreak of invasive aspergillosis. Infect Control Hosp Epidemiol 1994;15:303-6.
125. Girardin H, Sarfati J, Traore F, Camet JD, Derouin F, Latge JP. Molecular epidemiology of nosocomial invasive aspergillosis. J Clin Microbiol 1994;32:684-90.
126. Hajjeh RA, Warnock DW. Counterpoint: invasive aspergillosis and the environment: rethinking our approach to prevention. Clin Infect Dis 2001;33:1549-52.
127. Anaissie EJ, Stratton SL, Dignani MC, et al. Pathogenic Aspergillus species recovered from a hospital water system: a 3-year prospective study. Clin Infect Dis 2002;34:780-9.
128. Anaissie EJ, Stratton SL, Dignani MC, et al. Pathogenic molds (including Aspergillus species) in hospital water distribution systems: a 3-year prospective study and clinical implications for patients with hematologic malignancies. Blood 2003;101:2542-6.
129. Anaissie EJ, Stratton SL, Dignani MC, et al. Cleaning patient shower facilities: A novel approach to reducing patient exposure to aerosolized Aspergillus species and other opportunistic molds. Clin Infect Dis 2002;35:e86-8. Available from http://www.journals.uchicago.edu/CIF)/journal/contents/v35n8.html.
130. Debeaupuis JP, Sarfati J, Chazalet V, Latge JP. Genetic diversity among clinical and environmental isolates of Aspergillus fumigatus. Infect Immun 1997;65:3080-5.
131. Moore CB, Sayers N, Mosquera J, Slaven J, Denning DW. Antifungal drug resistance in Aspergillus. J Infect 2000;41:203-20.
132. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of conidium forming filamentous fungi: approved standard (M38-A). Wayne, PA: National Committee for Clinical Laboratory Standards, 2002.
133. Pfaller JB, Messer SA, Hollis RJ, Diekema DJ, Pfaller MA. In vitro susceptibility testing of Aspergillus spp.: comparison of Etest and reference microdilution methods for determining voriconazole and itraconazole MICs. J Clin Microbiol 2003;41:1126-9.
134. Rex JH, Pfaller MA, Walsh TJ, et al. Antifungal susceptibility testing: practical aspects and current challenges. Clin Microbiol Rev 2001;14:643-58.
135. Kontoyiannis DP, Lewis RE. Antifungal drug resistance of pathogenic fungi. Lancet 2002;359:1135-44.
136. Centers for Disease Control and Prevention. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. MMWR Recomm Rep 2000;49:1-125.
137. Schwartz S, Behre G, Heinemann V, et al. Aerosolized amphotericin B inhalations as prophylaxis of invasive Aspergillus infections during prolonged neutropenia: results of a prospective randomized multicenter trial. Blood 1999;93:3654-61.
138. van Burik J, Ratanatharathorn V, Lipton J, Miller C, Bunin N, Walsh TJ. Randomized, double-blind trial of micafungin versus fluconazole for the prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplantation. Presented at the 42nd interscience conference on antimicrobial agents and chemotherapy, San Diego, CA, September 27-30, 2002.
139. Bow EJ, Laverdiere M, Lussier N, Rotstein C, Cheang MS, Ioannou S. Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials. Cancer 2002;94:3230-46.
140. Marr KA, Crippa F, Leisenring W, et al. Itraconazole versus fluconazole for antifungal prophylaxis in allogeneic HSCT recipient: results of a randomized trial. Presented at the 44th annual meeting of the American Society of Hematology, Philadelphia, PA, December 6-10, 2002.
141. Winston DJ, Maziarz RT, Chandrasekar PH, et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients: a multicenter, randomized trial. Ann Intern Med 2003;138:705-13.
142. Pfizer Inc. Vfend (voriconazole) package insert. New York, NY; 2002.
143. Kontoyiannis DP, Hachem R, Lewis RE, Rivero G, Kantarjian H, Raad I. Efficacy and toxicity of caspofungin/liposomal amphotericin B combination in documented or possible invasive aspergillosis in patients with hematological malignancies. Presented at the 42nd interscience conference on antimicrobial agents and chemotherapy, San Diego, CA, September 27-30, 2002.
144. Kirkpatrick WR, Perea S, Coco BJ, Patterson TF. Efficacy of caspofungin alone and in combination with voriconazole in a Guinea pig model of invasive aspergillosis. Antimicrob Agents Chemother 2002;46:2564-8.
145. Petraitis V, Petraitiene R, Sarafandi AA, et al. Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. J Infect Dis 2003;187:1834-43.
146. Lewis RE, Kontoyiannis DP. Rationale for combination antifungal therapy. Pharmacotherapy 2001;21:149S-64.
147. Kontoyiannis DP. Why prior fluconazole use is associated with an increased risk of invasive mold infections in immunosuppressed hosts: an alternative hypothesis. Clin Infect Dis 2002;34:1281-3;author reply 1283. Erratum in: Clin Infect Dis 2002 Jul 1;35(1):110.
148. Kontoyiannis DP. Why prior fluconazole use is associated with an increased risk of invasive mold infections in immunosuppressed hosts: an alternative hypothesis. Clin Infect Dis 2002;34:1281-3;author reply 1283. Erratum in: Clin Infect Dis 2002 Jul 1;35(1):110.
149. Lewis RE, Prince RA, Chi J, Kontoyiannis DP. Itraconazole preexposure attenuates the efficacy of subsequent amphotericin B therapy in a murine model of acute invasive pulmonary aspergillosis. Antimicrob Agents Chemother 2002;46:3208-14.
150. Schaffner A, Bohler A. Amphotericin B refractory aspergillosis after itraconazole: evidence for significant antagonism. Mycoses 1993;36:421-4.
151. Stevens DA, Kullberg BJ, Brummer E, Casadevall A, Netea MG, Sugar AM. Combined treatment: antifungal drugs with antibodies, cytokines or drugs. Med Mycol 2000;38(suppl 1):305-15.
152. Stevens DA. Combination immunotherapy and antifungal chemotherapy. Clin Infect Dis 1998;26:1266-9.
153. Hubel K, Dale DC, Engert A, Liles WC. Current status of granulocyte (neutrophil) transfusion therapy for infectious diseases. J Infect Dis 2001;183:321-8.
154. Finiewicz K, Wingard JR. Cytokines and WBC transfusions. In: Rubenstein E, ed. Textbook of febrile neutropenia. London: Martin Dunitz, 2001.
155. Adkins DR, Goodnough LT, Shenoy S, et al. Effect of leukocyte compatibility on neutrophil increment after transfusion of granulocyte colony-stimulating factor-mobilized prophylactic granulocyte transfusions and on clinical outcomes after stem cell transplantation. Blood 2000;95:3605-12.